Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw unusually large options trading on Wednesday. Traders acquired 1,002 put options on the company. This is an increase of 1,791% compared to the typical volume of 53 put options.

Insider Transactions at Maravai LifeSciences

In other Maravai LifeSciences news, insider Carl Hull acquired 175,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the acquisition, the insider now owns 175,000 shares of the company’s stock, valued at approximately $987,000. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.63% of the company’s stock.

Institutional Trading of Maravai LifeSciences

Several institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its holdings in Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock valued at $33,658,000 after purchasing an additional 3,731,924 shares in the last quarter. Point72 DIFC Ltd bought a new position in shares of Maravai LifeSciences during the 3rd quarter worth approximately $22,108,000. Point72 Asset Management L.P. boosted its stake in Maravai LifeSciences by 149.6% in the 2nd quarter. Point72 Asset Management L.P. now owns 3,519,561 shares of the company’s stock valued at $25,200,000 after buying an additional 2,109,199 shares in the last quarter. Mackenzie Financial Corp grew its position in Maravai LifeSciences by 16.8% in the second quarter. Mackenzie Financial Corp now owns 5,860,641 shares of the company’s stock valued at $41,962,000 after acquiring an additional 844,325 shares during the period. Finally, Dragoneer Investment Group LLC acquired a new position in Maravai LifeSciences during the second quarter worth $5,373,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MRVI. Guggenheim began coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating for the company. Robert W. Baird decreased their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and reduced their price objective for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Finally, Wolfe Research assumed coverage on shares of Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.28.

Maravai LifeSciences Trading Up 1.7 %

Shares of MRVI opened at $5.32 on Thursday. The stock’s 50-day moving average price is $5.35 and its 200 day moving average price is $7.29. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -3.24 and a beta of -0.07. Maravai LifeSciences has a 12-month low of $4.28 and a 12-month high of $11.56.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, November 7th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $65.20 million during the quarter, compared to analyst estimates of $67.58 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. During the same quarter in the previous year, the company posted ($0.02) earnings per share. As a group, research analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.